Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Friday, May 9, 2025
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
Tags
Lynparza
Tag:
Lynparza
Latest Pharma-News
AZ’s Lynparza and Imfinzi combination shows positive results in advanced ovarian cancer
admin
-
April 6, 2023
0
Latest Pharma-News
Lynparza with abiraterone approved in EU for metastatic castration-resistant prostate cancer
admin
-
December 21, 2022
0
Latest Pharma-News
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment
admin
-
January 16, 2022
0
Latest Pharma-News
Lynparza with abiraterone delayed disease progression in PROpel Phase III trial
admin
-
September 24, 2021
0
Latest Pharma-News
Lynparza shows promise in preventing cancer recurrence
admin
-
June 4, 2021
0
Latest Pharma-News
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza crossed superiority boundary
admin
-
February 18, 2021
0
Latest Pharma-News
AstraZeneca’s Lynparza recommended for metastatic castration-resistant prostate cancer
admin
-
September 21, 2020
0
Latest Pharma-News
Lynparza approved in the EU for pancreatic cancer
admin
-
July 8, 2020
0
Latest Pharma-News
Lynparza recommended for approval in EU by CHMP
admin
-
June 1, 2020
0
Latest Pharma-News
FDA OK’s for Lynparza for metastatic castration-resistant prostate cancer
admin
-
May 20, 2020
0
Latest Pharma-News
Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
admin
-
May 12, 2020
0
Latest Pharma-News
Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
admin
-
April 24, 2020
0
- Advertisment -
Most Read
J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin
April 11, 2025
Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
April 9, 2025
Novartis receives FDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
April 9, 2025
AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025
April 9, 2025